Pantelis Litsardopoulos
Patra, ESYE23, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study group.
Journal: Cephalalgia : an international journal of headache
Published: June 04, 2026
Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group.
Journal: The journal of headache and pain
Published: November 29, 2025
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group.
Journal: European journal of neurology
Published: May 20, 2025
Gender and age effects on the incidence and severity of chemotherapy-induced neuropathic pain: a propensity score matching analysis.
Journal: BMC cancer
Published: February 19, 2025
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry.
Journal: Expert review of neurotherapeutics
Published: September 16, 2024
Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine.
Journal: Toxins
Published: January 16, 2024
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine.
Journal: Journal of clinical medicine
Published: December 14, 2023
Incidence and risk factors for developing chemotherapy-induced neuropathic pain in 500 cancer patients: A file-based observational study.
Journal: Journal of the peripheral nervous system : JPNS
Published: November 14, 2023
Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry.
Journal: Journal of clinical medicine
Published: June 02, 2023
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry.
Journal: Journal of clinical medicine
Published: April 13, 2023
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real-world data from a Greek registry.
Journal: European journal of neurology
Published: January 13, 2023
Last Updated: 09/26/2026